Muromonab-CD3 (Orthoclone OKT3®), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 38, Issue 5, 2006, Pages 365-370

  Benekli, M ^a   Hahn, T ^b   Williams, B T ^b   Cooper, M ^b   Roy, H N ^b   Wallace, P ^b   Stewart, C ^b   Bambach, B ^b   McCarthy Jr , P L ^b  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Allogeneic BMT; GVHD prophylaxis; Monoclonal antibody; OKT3

Indexed keywords

ACICLOVIR; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPHENHYDRAMINE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; OKT 3; PARACETAMOL; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANALYSIS OF VARIANCE; ANGIONEUROTIC EDEMA; ARTICLE; CANCER SURVIVAL; CHILL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HLA TYPING; HUMAN; IMMUNOPROPHYLAXIS; IN VIVO STUDY; INCIDENCE; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISEASE; MALE; MYALGIA; MYCOSIS; MYELOABLATIVE CONDITIONING; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SIBLING; SKIN DEFECT; STOMATITIS; SURVIVAL TIME; SYSTEMIC DISEASE; THRUSH; TREATMENT OUTCOME; TREMOR; UPPER RESPIRATORY TRACT INFECTION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTIGENS, CD3; BONE MARROW TRANSPLANTATION; CHILD; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MUROMONAB-CD3; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33747341351     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705450     Document Type: Article

References (20)

1. Cosimi AB. Clinical development of orthoclone OKT3. Transplant Proc 1987; 14 (Suppl 1): 7-16.
2. Hooks MA, Wade CS, Millikan WJ. Muromonab CD-3: A review of its pharmacology, pharmacokinetics and clinical use in transplantation. Pharmacotherapy 1991; 11: 26-37.
3. Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol 2000; 20: 108-125.
4. Gleixner B, Kolb HJ, Holler E, Liesenfeld S, Riedner C, Hiller E et al. Treatment of aGVHD with OKT3: Clinical outcome and side-effects associated with release of TNFa. Bone Marrow Transplant 1991; 8: 93-98.
5. Gratama JW, Jansen J, Filipovich RA, Tanke HJ, Goldstein G, Zwann FE. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Transplantation 1984; 38: 469-474.
6. Martin PJ, Hansen JA, Anasetti C, Zutter M, Durnam D, Storb R et al. Treatment of acute graft-versus-host disease with anti-CD3 monoclonal antibodies. Am J Kidney Dis 1988; 11: 149-152.
7. Hebart H, Ehninger G, Schmidt H, Berner B, Reuss-Borst M, Waller HD et al. Treatment of steroid-resistant acute graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TcR monoclonal antibodies. Bone Marrow Transplant 1995; 15: 891-894.
8. Filipovich AH, Krawczak CL, Kersey JH, McGlave P, Ramsay NK, Goldman A et al. Graft-vs.host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone marrow transplantation. Br J Haematol 1985; 60: 143-152.
9. Brown RA, Wolff SN, Fay JW, Pineiro L, Collins Jr RH, Lynch JP et al. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: A study by the North American Marrow Transplant Group. Blood 1995; 85: 1391-1395.
10. Alidina A, Lawrence D, Ford LA, Baer MR, Bambach B, Bernstein SH et al. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: Association with the female sex and cardiac risk factors. Biol Blood Marrow Transplant 1999; 5: 322-327.
11. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347-1353.
12. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
13. Stewart CC, Stewart SJ. Multiparameter data acquisition and analysis of leukocytes by flow cytometry. In: Darzynkiewicz Z, Robinson JP, Crissman HA (eds). Methods of Cell Biology, Vol. 64. Academic Press, Inc.: New York, 2001, pp 289-312.
14. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
15. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A matched sibling donors. Transplantation 1974; 18: 295-304.
16. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
17. Hahn T, McCarthy PL, Zhang MJ, Sobocinski K, Barrett AJ, Ringden O et al. Risk factors for acute GVHD after related HLA-matched allogeneic blood or marrow transplant. Proc AACR 2006; 47, Abstract #2881.
18. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314.
19. Filipovich AH, McGlave PB, Ramsay NK, Goldstein G, Warkentin PI, Kesey JH. Pretreatment of donor bone marrow with monoclonal antibody OKT-3 for prevention of acute graft-versus-host disease in histocompatible bone marrow transplantation. Lancet 1982; 1: 1266-1269.
20. Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 465-471.